Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas

被引:16
作者
Hsieh, Sheng-Hwu [1 ]
Shih, Kuang-Chung [2 ]
Chou, Chien-Wen [3 ]
Chu, Chih-Hsun [4 ]
机构
[1] Chang Gung Univ, Div Endocrinol & Metab, Chang Gung Mem Hosp, Coll Med, Tao Yuan 333, Taiwan
[2] Tri Serv Gen Hosp, Natl Def Med Ctr, Div Endocrinol & Metab, Taipei 114, Taiwan
[3] Chi Mei Med Ctr, Div Endocrinol & Metab, Tainan, Taiwan
[4] Kaohsiung Vet Gen Hosp, Div Endocrinol & Metab, Kaohsiung, Taiwan
关键词
alpha-Glucosidase inhibitors; Miglitol; Type 2 diabetes mellitus; ALPHA-GLUCOSIDASE INHIBITOR; ACARBOSE; NIDDM; PIOGLITAZONE; PHARMACOLOGY; REDUCTION; MORTALITY; THERAPY;
D O I
10.1007/s00592-010-0220-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study is to examine the efficacy and tolerability of miglitol with respect to improving glycemic control in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylurea treatment. This was a randomized, double-blinded, placebo-controlled, multicenter study. A total of 105 patients were randomized to receive 24 weeks of treatment with miglitol (n = 52; titrated from 50 mg to 100 mg 3 times daily) or placebo (n = 53). Concomitant sulfonylurea treatment and diet remained unchanged. The primary endpoint was change in glycated hemoglobin (HbA1c) from baseline at 24 weeks. Secondary endpoints were changes in fasting plasma glucose (FPG), postprandial plasma glucose (PPG), and postprandial serum insulin (PSI). The miglitol treatment group showed significantly greater reductions in HbA1c and PPG levels compared with the placebo group. With respect to adverse events, abdominal discomfort, diarrhea, and hypoglycemia occurred with similar frequency in both groups. Results of this study indicate that miglitol significantly improves metabolic control in Chinese patients with type 2 diabetes mellitus. Miglitol is safe and well tolerated, with the exception of abdominal discomfort. Therefore, miglitol may be a useful adjuvant therapy for Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylurea treatment.
引用
收藏
页码:71 / 77
页数:7
相关论文
共 31 条
[1]  
Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[2]   Acarbose-associated hepatotoxicity [J].
Andrade, RJ ;
Lucena, M ;
Vega, JL ;
Torres, M ;
Salmerón, FJ ;
Bellot, V ;
Garcia-Escaño, MD ;
Moreno, P .
DIABETES CARE, 1998, 21 (11) :2029-2030
[3]   ACARBOSE - AN UPDATE OF ITS PHARMACOLOGY AND THERAPEUTIC USE IN DIABETES-MELLITUS [J].
BALFOUR, JA ;
MCTAVISH, D .
DRUGS, 1993, 46 (06) :1025-1054
[4]  
BISCHOFF H, 1994, EUR J CLIN INVEST, V24, P3
[5]   Acarbose: Its role in the treatment of diabetes mellitus [J].
Campbell, LK ;
White, JR ;
Campbell, RK .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (11) :1255-1262
[6]   The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes [J].
Chiasson, JL ;
Naditch, L .
DIABETES CARE, 2001, 24 (06) :989-994
[7]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[8]   REDUCTION OF GLYCOSYLATED HEMOGLOBIN AND POSTPRANDIAL HYPERGLYCEMIA BY ACARBOSE IN PATIENTS WITH NIDDM - A PLACEBO-CONTROLLED DOSE-COMPARISON STUDY [J].
CONIFF, RF ;
SHAPIRO, JA ;
ROBBINS, D ;
KLEINFIELD, R ;
SEATON, TB ;
BEISSWENGER, P ;
MCGILL, JB .
DIABETES CARE, 1995, 18 (06) :817-824
[9]   Acarbose-induced acute hepatitis [J].
Diaz-Gutierrez, FL ;
Ladero, JM ;
Diaz-Rubio, M .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (03) :481-481
[10]   Clinical trials with thiazolidinediones in subjects with Type 2 diabetes - is pioglitazone any different from rosiglitazone? [J].
Doggrell, Sheila A. .
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (03) :405-420